Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Exelixis (EXEL) to Report Q4 Earnings: What's in Store?

Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Exelixis (EXEL) closed at $22.60, marking a -0.96% move from the previous day.

Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 17th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Exelixis (EXEL) closed at $23.76, marking a -1.29% move from the previous day.

Is Exelixis (EXEL) Outperforming Other Medical Stocks This Year?

Is (EXEL) Outperforming Other Medical Stocks This Year?

Ryan McQueeney headshot

Top 10 Stocks Under $20

Today we've highlighted ten stocks that are currently trading for under $20 per share. These stocks currently have seen positive earnings estimate revisions, and a variety of other factors make these companies stand out as having strong upside potential.

Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure

Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.

5 Excellent GARP Picks With Cheap PEG Ratio

Although PEG ratio is categorized under value investing, this strategy follows the principles of both growth and value investing.

Kinjel Shah headshot

5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

A low key week for the biotech sector with focus on regular pipeline updates.

Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

Why Exelixis (EXEL) Could Be Positioned for a Surge

Exelixis (EXEL) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Is Exelixis (EXEL) Up 35.9% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss

Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.

Sarepta Stock More Than Doubles This Year So Far: Here's Why

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

Top Ranked Momentum Stocks to Buy for November 16th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th

Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx

Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.

Can Exelixis (EXEL) Run Higher on Rising Earnings Estimates?

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales

Exelixis's (EXEL) earnings and revenue beat expectations in the third-quarter propelled by strong sales of Cabometyx.

Exelixis (EXEL) to Report Q3 Earnings: What's in Store?

Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.